Álvarez-Zaballos Sara, Martínez-Sellés Manuel
Cardiology Department, Hospital General Universitario Gregorio Marañón, CIBERCV, 28007 Madrid, Spain.
School of Health and Biomedical Sciences, Universidad Europea, 28670 Madrid, Spain.
Front Biosci (Landmark Ed). 2023 Jul 26;28(7):150. doi: 10.31083/j.fbl2807150.
Pharmacotherapy is the cornerstone treatment for patients with heart failure (HF) that uses drugs targeting the renin-angiotensin-aldosterone system (RAAS), including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan. This article reviews the pathophysiology of the RAAS and the neurohormonal changes seen in patients with HF as well as the targets and the mode of action of these drugs. We also assess the role of ACE in ventricular remodeling and summarize the main evidence for the use of ACE-related drugs in HF patients.
药物治疗是心力衰竭（HF）患者的基石治疗方法，它使用针对肾素-血管紧张素-醛固酮系统（RAAS）的药物，包括血管紧张素转换酶（ACE）抑制剂、血管紧张素受体阻滞剂（ARB）以及血管紧张素受体-脑啡肽酶抑制剂（ARNI）沙库巴曲/缬沙坦。本文综述了RAAS的病理生理学以及HF患者中出现的神经激素变化，以及这些药物的靶点和作用方式。我们还评估了ACE在心室重构中的作用，并总结了在HF患者中使用ACE相关药物的主要证据。
